Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $100.00 | Overweight | Barclays |
| 11/20/2025 | $100.00 | Outperform | Mizuho |
| 6/2/2025 | $75.00 | Outperform | Oppenheimer |
| 5/27/2025 | $72.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $19.00 | Neutral | Goldman |
| 7/18/2023 | $44.00 | Outperform | William Blair |
| 5/18/2023 | Buy | Guggenheim | |
| 8/1/2022 | $40.00 | Overweight | Barclays |
Barclays initiated coverage of Tarsus Pharmaceuticals with a rating of Overweight and set a new price target of $100.00
Mizuho initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $100.00
Oppenheimer resumed coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $75.00
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
3 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and recent business achievements.
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing i
S-8 - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
10-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and recent business achievements.
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing i
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to host conference call today, November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the third quarter ended September 30, 2025. "Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we're having on patie
SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris